Effects of raloxifene co-administration on bone histomorphometric change in rats treated with GnRHa
Küçük Resim Yok
Tarih
2005
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: This study was carried out to show the changes in bone structure by histomorphometric analysis in rats administered GnRHa and to evaluate the effectiveness of raloxifene to revert bone changes related to analog administration. Study Design: Three months of female rats were divided into three groups. Group 2 and 3 were subcutaneously administered of leuprolin acetate, while group 1 was administered saline solution every 4 weeks. GnRHa therapy lasted 16 weeks, and raloxifene, as an add-back agent, were given at 8 weeks of treatment in group 3, meanwhile other groups were administered oral saline solution. At the end of the forth month, right tibia bone histomorphometric analysis were done in the three groups. Results: Bone histomorphometric examination showed that GnRHa administration decreased bone volume (20.8±7.3% vs. 17.3±3%), trabecular thickness (55±4 mm vs. 49.4±10.7 mm) and cortical thickness (290.6±26 mm vs. 261.9±35.6 mm). Concurrent treatment with raloxifene attenuated all of the changes in bone histomorphometric parameters found in GnRHa-treated rats. Administration of raloxifene also reduced bone turnover despite the significantly increasing bone volume and osteoblast surface compared with GnRHa-alone treatment (29.5±5.9% vs. 17.3±3%, 6.7±1.2% vs. 4.2±1%, P<0.01, respectively). Conclusion: These results imply that during long-term GnRHa treatment concurrent administration of raloxifene might be useful for protection of both trabecular and cortical bone loss.
Açıklama
Anahtar Kelimeler
Kaynak
GORM:Gynecology Obstetrics & Reproductive Medicine
WoS Q Değeri
Scopus Q Değeri
Cilt
11
Sayı
2
